Abstract: Aspects of the disclosure are drawn to methods for producing a fused connector termination. An exemplary method may include setting a specification requirement to be met by the fused connector termination and applying an amount of heat to a proximal region of an unfused connector termination. The proximal region of the unfused connector termination may include an inner optical fiber coaxially positioned within an outer ferrule, and applying the amount of heat may at least partially fuse the optical fiber to the outer ferrule to form an at least partially fused connector termination. The method may also include imaging the proximal region of the at least partially fused connector termination and determining, based on the imaging, whether the proximal region of the at least partially fused connector termination meets the specification.

Abstract: Computer vision grouping recognition is provided by receiving training images that include unpackaged items; identifying, by a computer vision model, a candidate identities for unpackaged items in a given training image; receiving, from a human user, a selected identity for the unpackaged item as feedback for the candidate identity; constructing a confusion matrix tallying matches and mismatches between candidate identities and the selected identities as analyzed across the training images for each unpackaged item; identifying at least one product category that includes at least a first unpackaged item and a second unpackaged item that the confusion matrix indicates as being misidentified for each other by the computer vision model; and reconfiguring the computer vision model to identify the product category instead of the first unpackaged item or the second unpackaged item when analyzing a given image including one or more of the first unpackaged item or the second unpackaged item.

Abstract: Computer vision grouping recognition is provided by receiving training images that include unpackaged items; identifying, by a computer vision model, a candidate identities for unpackaged items in a given training image; receiving, from a human user, a selected identity for the unpackaged item as feedback for the candidate identity; constructing a confusion matrix tallying matches and mismatches between candidate identities and the selected identities as analyzed across the training images for each unpackaged item; identifying at least one product category that includes at least a first unpackaged item and a second unpackaged item that the confusion matrix indicates as being misidentified for each other by the computer vision model; and reconfiguring the computer vision model to identify the product category instead of the first unpackaged item or the second unpackaged item when analyzing a given image including one or more of the first unpackaged item or the second unpackaged item.

Abstract: The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.

Abstract: The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.

Abstract: Computer vision grouping recognition is provided by receiving training images that include unpackaged items; identifying, by a computer vision model, a candidate identities for unpackaged items in a given training image; receiving, from a human user, a selected identity for the unpackaged item as feedback for the candidate identity; constructing a confusion matrix tallying matches and mismatches between candidate identities and the selected identities as analyzed across the training images for each unpackaged item; identifying at least one product category that includes at least a first unpackaged item and a second unpackaged item that the confusion matrix indicates as being misidentified for each other by the computer vision model; and reconfiguring the computer vision model to identify the product category instead of the first unpackaged item or the second unpackaged item when analyzing a given image including one or more of the first unpackaged item or the second unpackaged item.

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.

Abstract: A pressure sensor assembly includes a pressure sensor having a support structure and a sapphire isolation member coupled to the support structure and forming a region between a first surface of the sapphire isolation member and the support structure. A second surface of the sapphire isolation member has a sapphire etch surface formed thereon and is positioned to interface with fluid from or coupled to a process. A process seal is positioned against the second surface of the sapphire isolation member to prevent fluid from passing by the pressure sensor assembly. Electrical leads couple to a polysilicon strain gauge pattern positioned in the region on the first surface of the sapphire isolation member, and the polysilicon strain gauge pattern is configured to generate electrical signals indicative of the pressure of the fluid when the sapphire isolation member deflects responsive to the pressure.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.

Abstract: A pressure sensor assembly includes a pressure sensor having a support structure and a sapphire isolation member coupled to the support structure and forming a region between a first surface of the sapphire isolation member and the support structure. A second surface of the sapphire isolation member is positioned to interface with fluid from or coupled to a process. Electrical leads couple to a polysilicon strain gauge pattern positioned in the region on the first surface of the sapphire isolation member, and the polysilicon strain gauge pattern is configured to generate electrical signals indicative of the pressure of the fluid when the sapphire isolation member deflects responsive to the pressure.

Abstract: A process pressure transmitter includes transmitter electronics disposed within a housing coupled to a pressure sensor formed by a cell body defining an interior cavity. A deflectable diaphragm separates the interior cavity into a first cavity and a second cavity. The deflectable diaphragm includes a groove region located around a periphery of the deflectable diaphragm.

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: A process pressure transmitter includes transmitter electronics disposed within a housing. The transmitter electronics includes a communications circuit coupled to a processing system and an analog to digital converter disposed within the housing. The analog to digital converter electrically is coupled to the transmitter electronics. A pressure sensor comprises a cell body defining an interior cavity. A deflectable diaphragm comprising a second material is coupled to the cell body and separates the interior cavity into a first cavity and a second cavity. The deflectable diaphragm includes a groove region located around a periphery of the deflectable diaphragm. The first and second cavities each contain a dielectric fill-fluid, each of the fill fluids adapted to receive a pressure and exert a corresponding force on the diaphragm, and the diaphragm is deflectable in response to differences in the pressures received by the fill-fluids in the first and second cavities.

Abstract: A sensor body cell for use in a pressure sensor includes a metal housing and an insulating cell. The metal housing has a first cavity with a first conical inner surface. A portion of the first conical inner surface is concave. The insulating cell includes a first seal portion within the first cavity and forms a seal with the first conical inner surface.

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: A CPR training device is disclosed comprising a first member including a mouthpiece portion and a first engaging portion, a second member including an output portion and a second engaging portion, and an air passageway. The first engaging portion and the second engaging portion cooperates to form a filter seating arrangement at a filter seat position when assembled together to secure a filter within the CPR training device. The air passageway is open to air outside of the CPR training device only through the mouthpiece portion and the output portion. The filter is disposed in the air passageway at the filter seat position.

Abstract: A sensor body cell for use in a pressure sensor includes a metal housing and an insulating cell. The metal housing has a first cavity with a first conical inner surface. A portion of the first conical inner surface is concave. The insulating cell includes a first seal portion within the first cavity and forms a seal with the first conical inner surface.

Abstract: A CPR training device is disclosed comprising a first member including a mouthpiece portion and a first engaging portion, a second member including an output portion and a second engaging portion, and an air passageway. The first engaging portion and the second engaging portion cooperates to form a filter seating arrangement at a filter seat position when assembled together to secure a filter within the CPR training device. The air passageway is open to air outside of the CPR training device only through the mouthpiece portion and the output portion. The filter is disposed in the air passageway at the filter seat position.

Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.